![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » IND SWIFT GETS DCGI NOD FOR NEW DRUG
IND SWIFT GETS DCGI NOD FOR NEW DRUG
August 24, 2005
Drug-maker Ind Swift Laboratories Ltd today said it has received the approval from the Drug Controller General of India (DCGI) for its newly-developed anti-diarrhoea plus anti-bacterial drug and also announced its plans to launch the combination next month. ''The drug has successfully completed all stages of clinical trials and the company expects to launch it next month,'' V K Mehta, Managing Director, Ind Swift said. The drug is a combination of 500 mg Nitazoxanide (anti-diarrhoea agent) plus 200 mg Oflxacin (quinoline derivative).
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct